55592-10-4

Downstream Products

• 55592-11-5 11-<3'-(benzoyloxy)-17'-oxoestra-1',3',5'(10')-trien-7'α-yl>undecanoic acid 
• 251941-63-6 4-[(7R,8R,9S,13S,14S,17S)-7-(11-Azido-undecyl)-13-methyl-17-(tetrahydro-pyran-2-yloxy)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yloxymethyl]-3-nitro-benzoic acid methyl ester 
• 251941-64-7 4-[(7R,8R,9S,13S,14S,17S)-7-(11-Azido-undecyl)-13-methyl-17-(tetrahydro-pyran-2-yloxy)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yloxymethyl]-3-nitro-benzoic acid 
• 251941-61-4 Benzoic acid (7R,8R,9S,13S,14S,17S)-7-(11-bromo-undecyl)-13-methyl-17-(tetrahydro-pyran-2-yloxy)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl ester 
• 131811-95-5 N-n-butyl-N-methyl-11-(3'-(benzoyloxy)-17'-oxoestra-1',3',5'(10')-trien-7'α-yl)undecanamide 
• 251941-60-3 Benzoic acid (7R,8R,9S,13S,14S,17S)-7-(11-bromo-undecyl)-17-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl ester 

Relevant academic research and scientific papers

Anti-estrogenic compounds and compositions

Inhibitors of sex steroid activity, for example those having the general structure STR1 may be used as part of a pharmaceutical composition to provide antiestrogenic effects and/or to suppress estrogen synthesis. Such pharmaceutical compositions are useful for the treatment of breast cancer or other diseases whose progress is aided by activation of sex steroid receptors.

Estrogen nucleus derivatives for use in inhibition of sex steroid activity

Novel compounds for the inhibition of sex steroid activity for the treatment of both androgen-related and estrogen-related diseases include for example 15- and 16-halo substituted compounds such as: STR1 The compounds are characterized by an estrogenic nucleus substituted with a substituent of the formula --R1 [B--R2 --]x L--G wherein at least one of L and G is a polar moiety distanced from a ring carbon of the estrogenic nucleus by a least three intervening atoms: x is an integer from 0-6; R1 and R2 are independently either absent or selected from the group consisting of straight- or branched-chain alkylene, straight- or branched-chain alkynylene, straight- or branched-chain alkenylene, phenylene, and fluoro-substituted analogs of the foregoing; and B is either absent or selected from the group consisting of --O--, --Se--, --SO--, --SO2 --, --NR3 --, --SiR32, --CR3 OR3 --, NR3 CO--, NR3 CS--, --CONR3 --, CSNR3 --, --COO--, --COS--, --SCO--, --CSS--, --SCS--, --OCO-- and phenylene (R3 being hydrogen or lower alkyl).